Anders Lannergård

Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden

Kågström, Elsa; Lannergård, Anders; El Khosht, J.; Lörelius, P. et al.

Ingår i Harm Reduction Journal, 2023

• DOI för Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden
• Ladda ner fulltext (pdf) av Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden

Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway

Kjellin, Midori; Kileng, Hege; Akaberi, Dario; Palanisamy, Navaneethan et al.

Ingår i Scandinavian Journal of Gastroenterology, s. 1042-1050, 2019

• DOI för Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway
• Ladda ner fulltext (pdf) av Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway

The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort

Kjellin, Midori; Wesslén, Terése; Löfblad, Erik; Lennerstrand, Johan et al.

Ingår i Upsala Journal of Medical Sciences, s. 50-56, 2018

• DOI för The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort
• Ladda ner fulltext (pdf) av The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort

Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study

Sundberg, Isak; Lannergård, Anders; Ramklint, Mia; Cunningham, Janet L

Ingår i BMC Psychiatry, 2018

• DOI för Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study
• Ladda ner fulltext (pdf) av Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study

Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.

Kileng, Hege; Kjellin, Midori; Akaberi, Dario; Bergfors, Assar et al.

Ingår i Scandinavian Journal of Gastroenterology, s. 1347-1353, 2018

• DOI för Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.
• Ladda ner fulltext (pdf) av Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.

Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden

Kågström, Elsa; Lannergård, Anders; El Khosht, J.; Lörelius, P. et al.

Ingår i Harm Reduction Journal, 2023

• DOI för Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden
• Ladda ner fulltext (pdf) av Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden

Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway

Kjellin, Midori; Kileng, Hege; Akaberi, Dario; Palanisamy, Navaneethan et al.

Ingår i Scandinavian Journal of Gastroenterology, s. 1042-1050, 2019

• DOI för Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway
• Ladda ner fulltext (pdf) av Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway

The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort

Kjellin, Midori; Wesslén, Terése; Löfblad, Erik; Lennerstrand, Johan et al.

Ingår i Upsala Journal of Medical Sciences, s. 50-56, 2018

• DOI för The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort
• Ladda ner fulltext (pdf) av The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort

Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study

Sundberg, Isak; Lannergård, Anders; Ramklint, Mia; Cunningham, Janet L

Ingår i BMC Psychiatry, 2018

• DOI för Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study
• Ladda ner fulltext (pdf) av Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study

Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.

Kileng, Hege; Kjellin, Midori; Akaberi, Dario; Bergfors, Assar et al.

Ingår i Scandinavian Journal of Gastroenterology, s. 1347-1353, 2018

• DOI för Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.
• Ladda ner fulltext (pdf) av Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.

Enhanced Systemic Response of Matrix Metalloproteinases and Their Regulators in Campylobacter and Salmonella Patients

Nilsson, Anna J. E.; Tervahartiala, Taina; Lennebratt, David; Lannergård, Anders et al.

Ingår i Diagnostics (Basel), 2018

• DOI för Enhanced Systemic Response of Matrix Metalloproteinases and Their Regulators in Campylobacter and Salmonella Patients
• Ladda ner fulltext (pdf) av Enhanced Systemic Response of Matrix Metalloproteinases and Their Regulators in Campylobacter and Salmonella Patients

Inflammatory Cytokines in a Repeated Measures Prospective Case Study of Interferon-Induced Depression

Sundberg, Isak; Lannergård, Anders; Ramklint, Mia; Cunningham, Janet

Ingår i Biological Psychiatry, 2017

• DOI för Inflammatory Cytokines in a Repeated Measures Prospective Case Study of Interferon-Induced Depression

A trial with IgY chicken antibodies to eradicate faecal carriage of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta-lactamases

Jonsson, Anna-Karin; Larsson, Anders; Tängdén, Thomas; Melhus, Åsa et al.

Ingår i Infection Ecology & Epidemiology, 2015

• DOI för A trial with IgY chicken antibodies to eradicate faecal carriage of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta-lactamases

Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden

Lindstrom, Ida; Kjellin, Midori; Palanisamy, Navaneethan; Bondeson, Kare et al.

Ingår i INFECTIOUS DISEASES, s. 555-562, 2015

• DOI för Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden

Vanligt med antibiotikaresistens hos barn med urinvägsavledning

Lindell, Fredrik; Barker, Gillian; Lannergård, Anders

Ingår i Läkartidningen, s. 2376-2379, 2011

Diagnostik vid virala hepatiter i ett kliniskt perspektiv

Lannergård, Anders

Ingår i Klinisk biokemi i Norden, s. 10-14, 2010

The time course of body temperature, serum amyloid A protein, C-reactive protein and interleukin-6 in patients with bacterial infection during the initial 3 days of antibiotic therapy

Lannergård, Anders; Viberg, Anders; Cars, Otto; Karlsson, Mats O. et al.

Ingår i Scandinavian Journal of Infectious Diseases, s. 663-671, 2009

• DOI för The time course of body temperature, serum amyloid A protein, C-reactive protein and interleukin-6 in patients with bacterial infection during the initial 3 days of antibiotic therapy

Human serum amyloid A (SAA) and high sensitive C-reactive protein (hsCRP) in preterm newborn infants with nosocomial infections

Lannergård, Anders; Larsson, Anders; Friman, Göran; Ewald, Uwe

Ingår i Acta Paediatrica, s. 1061-1065, 2008

• DOI för Human serum amyloid A (SAA) and high sensitive C-reactive protein (hsCRP) in preterm newborn infants with nosocomial infections

A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function

Viberg, Anders; Lannergård, Anders; Larsson, Anders; Cars, Otto et al.

Ingår i British Journal of Clinical Pharmacology, s. 297-303, 2006

• DOI för A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function

Serum amyloid A (SAA) protein and high-sensitivity C-reactive protein (hsCRP) in healthy newborn infants and healthy young through elderly adults

Lannergård, Anders; Friman, Göran; Ewald, Uwe; Lind, Lars et al.

Ingår i Acta Paediatrica, s. 1198-1202, 2005